» Articles » PMID: 12473600

Microvessel Density, Expression of Estrogen Receptor Alpha, MIB-1, P53, and C-erbB-2 in Inflammatory Breast Cancer

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2002 Dec 11
PMID 12473600
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose And Experimental Design: The purpose is to define intratumoral microvessel density (MVD) and potential biological markers that correlate with inflammatory breast cancer (IBC), we examined MVD, estrogen receptor a (ER) status, MIB-1 proliferation index, p53, and c-erbB-2 by immunohistochemistry in archival specimens from 67 women diagnosed with breast cancer with or without the inflammatory phenotype at the Institut Salah Azaiz (Tunis, Tunisia).

Results: The moderate (25-50/x400 field) to high microvessel count (>50/x400 field) was observed in 23 (51%) of 45 IBC tumors compared with 3 (14%) of 22 non-IBC tumors (P = 0.0031; chi(2) test). The presence of ER was found in 6 (14%) of 44 cases versus 7 (32%) of 22 cases in IBC and non-IBC, respectively (P = 0.10). In this series of 67 patient tumors, the median MVD count in ER-negative breast tumors was 21, whereas the median count was 4 in ER-positive breast tumors (P = 0.08; Wilcoxon rank-sum test). However, MIB-1, p53, and c-erbB-2 were not significantly different between IBC and non-IBC tumors. The intratumoral MVD between IBC and non-IBC was still statistically significant after adjustment for multiple comparisons (P = 0.02; Bonferroni test).

Conclusions: These data suggest that there is an increased MVD in breast cancer with the inflammatory phenotype as compared with breast cancer without the inflammatory phenotype.

Citing Articles

Pathological and molecular characteristics of inflammatory breast cancer.

di Bonito M, Cantile M, Botti G Transl Cancer Res. 2022; 8(Suppl 5):S449-S456.

PMID: 35117122 PMC: 8798351. DOI: 10.21037/tcr.2019.03.24.


Prediction of Inflammatory Breast Cancer Survival Outcomes Using Computed Tomography-Based Texture Analysis.

Song S, Seo B, Cho K, Woo O, Ganeshan B, Kim E Front Bioeng Biotechnol. 2021; 9:695305.

PMID: 34354986 PMC: 8329959. DOI: 10.3389/fbioe.2021.695305.


PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer.

Bertucci A, Bertucci F, Zemmour C, Lerebours F, Pierga J, Levy C Front Oncol. 2020; 10:575978.

PMID: 33330051 PMC: 7732675. DOI: 10.3389/fonc.2020.575978.


Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility.

Dobiasova B, Mego M Breast Cancer (Dove Med Press). 2020; 12:153-163.

PMID: 33116817 PMC: 7569067. DOI: 10.2147/BCTT.S231502.


Targeting Signaling Pathways in Inflammatory Breast Cancer.

Wang X, Semba T, Thi Hanh Phi L, Chainitikun S, Iwase T, Lim B Cancers (Basel). 2020; 12(9).

PMID: 32883032 PMC: 7563157. DOI: 10.3390/cancers12092479.